Clinical significance of YAP1 activation in head and neck squamous cell carcinomaopen access
- Authors
- Eun, Young-Gyu; Lee, Dongjin; Lee, Young Chan; Sohn, Bo Hwa; Kim, Eui Hyun; Yim, Sun Young; Kwon, Kee Hwan; Lee, Ju-Seog
- Issue Date
- 19-Dec-2017
- Publisher
- IMPACT JOURNALS LLC
- Keywords
- YAP1; gene signature; head and neck cancer; prognosis
- Citation
- ONCOTARGET, v.8, no.67, pp 111130 - 111143
- Pages
- 14
- Indexed
- SCIE
SCOPUS
- Journal Title
- ONCOTARGET
- Volume
- 8
- Number
- 67
- Start Page
- 111130
- End Page
- 111143
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/29262
- DOI
- 10.18632/oncotarget.22666
- ISSN
- 1949-2553
1949-2553
- Abstract
- By analyzing the genomic data of head and neck squamous cell cancer (HNSCC), we investigated clinical significance of YAP1 activation. Copy number and mRNA expression of YAP1 were analyzed together to assess clinical relevance of YAP1 activation in HNSCC. The clinical significance of YAP1 activation was further validated in four independent test cohorts. We also assessed the correlation of YAP1 activation with genomic alterations such as copy number alteration, somatic mutation, and miRNA expression. The YAP1-activated (YA) subgroup showed worse prognosis for HNSCC as tested and validated in five cohorts. In a multivariate risk analysis, the YAP1 signature was the most significant predictor of overall survival. The YAP1-inactivated (YI) subgroup was associated with HPV-positive status. In multiplatform analysis, YA tumors had gain of EGFR and SNAI2; loss of tumor-suppressor genes such as CSMD1, CDKN2A, NOTCH1, and SMAD4; and high mutation rates of TP53 and CDKN2A. YI tumors were characterized by gain of PIK3CA, SOX2, and TP63; deletion of 11q23.1; and high mutation rates of NFE2L2, PTEN, SYNE1, and NSD1. YA tumors also showed weaker immune activity as reflected in low IFNG composite scores and YAP1 activity is negatively associated with potential response to treatment of pembrolizumab. In conclusion, activation of YAP1 is associated with worse prognosis of patients with HNSCC and potential resistance to immunotherapy.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.